- Biocon Biologics has received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its biosimilar Ustekinumab BS.
- This biosimilar is a substitute for Johnson & …
Join the vibrant privacy-ensured Dzambhala community on
Want to give feedback on this story? Write to us at [email protected]